Reviva Pharmaceuticals Holdings(RVPH)
$0.36+0.01 (+1.43%)
RVPH
Reviva Pharmaceuticals Holdings financials statements
$0.36
At close:+0.01 (+1.43%)
Want to see RVPH full AI Analyst Report?
Reviva Pharmaceuticals Holdings (RVPH) Ratios
1,273 Followers
Reviva Pharmaceuticals Holdings Ratios
RVPH's free cash flow for Q3 2026 was $-2.18T. For the 2026 fiscal year, RVPH's free cash flow was increased by $0.00 and operating cash flow was $-2.18T. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.08 | 1.01 | 1.38 | 1.90 | 13.39 |
| Quick Ratio | 2.08 | 1.01 | 1.38 | 1.90 | 13.39 |
| Cash Ratio | 1.98 | 0.92 | 1.36 | 1.86 | 12.66 |
| Solvency Ratio | -2.73 | 0.06 | 0.01 | -2.29 | -3.14 |
| Operating Cash Flow Ratio | -3.38 | -2.30 | -1.65 | -1.90 | -4.55 |
| Short-Term Operating Cash Flow Coverage | -60.45 | -73.22 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 7.83M | $ -7.15K | $ 5.72M | $ 8.39M | $ 28.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.05 | 0.56 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.04 | 0.36 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.84 | 19.08 | 4.14 | 2.25 | 1.09 |
| Debt Service Coverage Ratio | -47.23 | -62.73 | -1163.15 | -132.02 | -4188.28 |
| Interest Coverage Ratio | -1507.24 | -1665.07 | -1171.35 | -132.97 | -4185.80 |
| Debt to Market Cap | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.12 | 0.29 | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | 0.71 | 0.44 | 0.60 | 0.77 | 2.94 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.10% | 100.07% | 100.04% | 100.09% | 100.07% |
| EBT Per EBIT | 98.25% | 97.08% | 99.34% | 100.05% | 84.28% |
| Return on Assets (ROA) | -124.75% | -192.99% | -165.65% | -128.62% | -27.14% |
| Return on Equity (ROE) | -229.71% | -3681.99% | -686.53% | -289.95% | -29.71% |
| Return on Capital Employed (ROCE) | -233.59% | -3416.09% | -605.39% | -271.23% | -34.77% |
| Return on Invested Capital (ROIC) | -223.09% | -2265.06% | -605.39% | -5.89% | -32.83% |
| Return on Tangible Assets | -124.75% | -192.99% | -165.65% | -128.62% | -27.14% |
| Earnings Yield | -98.13% | -49.87% | -32.03% | -29.34% | -19.94% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -6.78 | -20.24 | -1.19 | -0.97 | -0.72 |
| Free Cash Flow Per Share | -6.78 | -20.24 | -1.19 | -0.97 | -0.72 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -8385979.01 | -9441451.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -8385979.01 | -9441451.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -60.45 | -73.22 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -121.49% | -55.91% | -23.11% | -22.86% | -24.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.02 | -2.01 | -3.12 | -3.41 | -5.02 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.34 | 73.84 | 21.43 | 9.88 | 1.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.82 | -1.79 | -4.33 | -4.37 | -4.01 |
| Price-to-Operating Cash Flow Ratio | -0.82 | -1.79 | -4.33 | -4.37 | -4.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.04 | -0.23 | -0.02 | 0.09 |
| Enterprise Value Multiple | -0.31 | -1.57 | -2.53 | -2.67 | -1.29 |
| Enterprise Value | 6.21M | 46.98M | 99.19M | 64.43M | 13.06M |
| EV to EBITDA | -0.31 | -1.57 | -2.53 | -2.67 | -1.29 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.25 | -1.40 | -3.50 | -3.40 | -1.22 |
| EV to Operating Cash Flow | -0.25 | -1.40 | -3.50 | -3.40 | -1.22 |
| Tangible Book Value Per Share | 2.38 | 0.49 | 0.24 | 0.43 | 1.94 |
| Shareholders’ Equity Per Share | 2.38 | 0.49 | 0.24 | 0.43 | 1.94 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -5.48 | -18.05 | -1.65 | -1.25 | -0.58 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.84 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.24 | 1.12 | 0.72 | 0.78 | 1.25 |
Currency in USD

